Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › zoledronic acid

zoledronic acid

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of zoledronic acid

65 trials tracked of zoledronic acid: 45 in phase 3 or 4 and 10 with published results. The most-cited published study has 1020 citations.

65Trials tracked
45Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 15 Phase 3 30 Phase 2 16 Phase 1 1 Other / NA 3
  1. Phase 3 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Completed · 1,020 cited
  2. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 440 cited
  3. Phase 3 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed · 357 cited
  4. Phase 4 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis Completed · 104 cited
  5. Phase 4 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed · 69 cited
  6. Phase 4 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants Completed · 51 cited
Show 44 more trials
  1. Phase 3 Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation Completed · 40 cited
  2. Phase 3 An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Completed · 40 cited
  3. Phase 3 S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed · 39 cited
  4. Phase 4 Re-treatment of Participants With Paget's Disease Using Zoledronic Acid Completed · 18 cited
  5. Phase 4 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis Completed
  6. Phase 4 Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty Completed
  7. Phase 4 Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery Completed
  8. Phase 4 Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) Completed
  9. Phase 4 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Completed
  10. Phase 4 Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Completed
  11. Phase 4 Zoledronic Acid Administration in Acute Spinal Cord Injury Completed
  12. Phase 4 Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women Completed
  13. Phase 4 A Multiple Myeloma Trial in Patients With Bone Metastases Completed
  14. Phase 4 Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density Completed
  15. Phase 4 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed
  16. Phase 3 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Completed
  17. Phase 3 Zoledronic Acid in Acute Spinal Cord Injury Completed
  18. Phase 3 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed
  19. Phase 3 Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period Completed
  20. Phase 3 Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer Completed
  21. Phase 3 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs Completed
  22. Phase 3 The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer Completed
  23. Phase 3 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss Completed
  24. Phase 3 Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis Completed
  25. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer Completed
  26. Phase 3 Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older Completed
  27. Phase 3 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy Completed
  28. Phase 3 Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. Completed
  29. Phase 3 Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer Completed
  30. Phase 3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed
  31. Phase 3 The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss Completed
  32. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. Completed
  33. Phase 3 Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer Completed
  34. Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
  35. Phase 3 Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period Completed
  36. Phase 3 Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions Completed
  37. Phase 3 Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Completed
  38. Phase 3 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. Completed
  39. Phase 3 Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis) Completed
  40. Phase 2 Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Completed
  41. Phase 2 A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Completed
  42. Phase 2 Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases Completed
  43. Phase 2 Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates Completed
  44. Phase 2 Prevention of Bone Loss After Acute SCI by Zoledronic Acid Completed

Showing the 50 most-cited and recently-updated of 65 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Oncology RCT
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
May 1, 2026
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months
Diabetes & Endocrinology Meta-analysis
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months Men Get Osteoporosis Too — and Now We Know Which Drugs Win
This Bayesian network meta-analysis evaluated antiresorptive and anabolic pharmacological interventions in men with osteoporosis.
A new analysis of 18 clinical trials finds that bone-building drugs may outperform bone-preserving drugs for men with osteoporosis, especial…
Frontiers Apr 10, 2026